AIFM2 and cancer: FSP1 is a parallel ferroptosis regulatory mechanism to GPX4, inhibiting ferroptosis by modulating non-mitochondrial coenzyme Q. The combination pharmacological inhibition of FSP1 and GPX4 may be an effective strategy to sensitize cancer cells, especially those insensitive to GPX4 inhibitors alone, to ferroptosis-inducing chemotherapeutic agents (64).